Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Krystal Biotech

Nasdaq:KRYS
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KRYS
Nasdaq
$668M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Krystal Biotech has significant price volatility in the past 3 months.
KRYS Share Price and Events
7 Day Returns
-0.9%
NasdaqGM:KRYS
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
17%
NasdaqGM:KRYS
0%
US Biotechs
-11.5%
US Market
KRYS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Krystal Biotech (KRYS) -0.9% -26.7% -36% 17% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • KRYS outperformed the Biotechs industry which returned 0% over the past year.
  • KRYS outperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
KRYS
Industry
5yr Volatility vs Market
Related Companies

KRYS Value

 Is Krystal Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Krystal Biotech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Krystal Biotech.

NasdaqGM:KRYS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:KRYS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 21%) (0.49%))
1.139
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.139 * 5.44%)
7.94%

Discounted Cash Flow Calculation for NasdaqGM:KRYS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Krystal Biotech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:KRYS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.94%)
2020 -38.50 Analyst x1 -35.67
2021 -59.10 Analyst x1 -50.73
2022 -53.30 Analyst x1 -42.39
2023 -3.60 Analyst x1 -2.65
2024 68.60 Analyst x1 46.83
2025 113.99 Est @ 66.17% 72.09
2026 167.39 Est @ 46.84% 98.08
2027 223.15 Est @ 33.31% 121.14
2028 276.35 Est @ 23.84% 138.99
2029 323.91 Est @ 17.21% 150.93
Present value of next 10 years cash flows $496.00
NasdaqGM:KRYS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $323.91 × (1 + 1.74%) ÷ (7.94% – 1.74%)
$5,319.24
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,319.24 ÷ (1 + 7.94%)10
$2,478.64
NasdaqGM:KRYS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $496.00 + $2,478.64
$2,974.64
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,974.64 / 17.36
$171.37
NasdaqGM:KRYS Discount to Share Price
Calculation Result
Value per share (USD) From above. $171.37
Current discount Discount to share price of $38.50
= -1 x ($38.50 - $171.37) / $171.37
77.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Krystal Biotech is available for.
Intrinsic value
>50%
Share price is $38.5 vs Future cash flow value of $171.37
Current Discount Checks
For Krystal Biotech to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Krystal Biotech's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Krystal Biotech's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Krystal Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Krystal Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:KRYS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.20
NasdaqGM:KRYS Share Price ** NasdaqGM (2020-03-27) in USD $38.5
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Krystal Biotech.

NasdaqGM:KRYS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:KRYS Share Price ÷ EPS (both in USD)

= 38.5 ÷ -1.20

-32.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Krystal Biotech is loss making, we can't compare its value to the US Biotechs industry average.
  • Krystal Biotech is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Krystal Biotech's expected growth come at a high price?
Raw Data
NasdaqGM:KRYS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -32.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
40.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Krystal Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Krystal Biotech's assets?
Raw Data
NasdaqGM:KRYS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $11.69
NasdaqGM:KRYS Share Price * NasdaqGM (2020-03-27) in USD $38.5
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:KRYS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:KRYS Share Price ÷ Book Value per Share (both in USD)

= 38.5 ÷ 11.69

3.29x

* Primary Listing of Krystal Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Krystal Biotech is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Krystal Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Krystal Biotech has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

KRYS Future Performance

 How is Krystal Biotech expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Krystal Biotech expected to grow at an attractive rate?
  • Krystal Biotech's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Krystal Biotech's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Krystal Biotech's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:KRYS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:KRYS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 40.9%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:KRYS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:KRYS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 244 85 72 4
2023-12-31 125 7 -1 4
2022-12-31 56 -47 -42 5
2021-12-31 16 -55 -57 5
2020-12-31 0 -35 -48 7
2020-03-28
NasdaqGM:KRYS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -19 -19
2019-09-30 -15 -17
2019-06-30 -13 -16
2019-03-31 -10 -13
2018-12-31 -9 -11
2018-09-30 -8 -9
2018-06-30 -7 -11
2018-03-31 -6 -10
2017-12-31 -4 -8
2017-09-30 -3 -7
2017-06-30 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Krystal Biotech's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Krystal Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:KRYS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Krystal Biotech Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:KRYS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 3.73 8.93 -1.05 4.00
2023-12-31 0.35 4.54 -2.54 4.00
2022-12-31 -1.98 1.51 -4.50 4.00
2021-12-31 -2.89 -1.28 -5.76 5.00
2020-12-31 -2.59 -1.72 -4.30 6.00
2020-03-28
NasdaqGM:KRYS Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.20
2019-09-30 -1.17
2019-06-30 -1.20
2019-03-31 -1.05
2018-12-31 -0.97
2018-09-30 -0.83
2018-06-30 -1.26
2018-03-31 -1.36
2017-12-31 -1.48
2017-09-30 -1.95
2017-06-30 -0.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Krystal Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Krystal Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Krystal Biotech has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

KRYS Past Performance

  How has Krystal Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Krystal Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Krystal Biotech does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Krystal Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Krystal Biotech's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Krystal Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Krystal Biotech Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:KRYS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -19.09 6.47 15.62
2019-09-30 -17.44 6.08 14.07
2019-06-30 -15.92 5.68 12.10
2019-03-31 -12.85 4.93 9.41
2018-12-31 -10.89 4.16 7.76
2018-09-30 -8.57 3.15 6.05
2018-06-30 -11.09 2.83 5.49
2018-03-31 -9.58 2.18 4.41
2017-12-31 -7.92 1.56 3.21
2017-09-30 -7.15 1.37 2.52
2017-06-30 -2.20 0.71 1.41
2016-12-31 -1.15 0.40 0.74

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Krystal Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Krystal Biotech has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Krystal Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Krystal Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Krystal Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

KRYS Health

 How is Krystal Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Krystal Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Krystal Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Krystal Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Krystal Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Krystal Biotech has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Krystal Biotech Company Filings, last reported 2 months ago.

NasdaqGM:KRYS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 202.91 0.00 193.69
2019-09-30 207.65 0.00 203.21
2019-06-30 198.29 0.00 195.47
2019-03-31 109.49 0.00 106.63
2018-12-31 113.23 0.00 111.76
2018-09-30 52.29 0.00 52.29
2018-06-30 45.27 0.00 45.45
2018-03-31 47.40 0.00 47.23
2017-12-31 49.47 0.00 49.59
2017-09-30 50.20 0.00 52.57
2017-06-30 -0.83 4.14 3.52
2016-12-31 0.29 1.84 1.92
  • Krystal Biotech has no debt.
  • Krystal Biotech currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Krystal Biotech has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if Krystal Biotech has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Krystal Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Krystal Biotech has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

KRYS Dividends

 What is Krystal Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Krystal Biotech dividends. Estimated to be 0% next year.
If you bought $2,000 of Krystal Biotech shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Krystal Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Krystal Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:KRYS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:KRYS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Krystal Biotech has not reported any payouts.
  • Unable to verify if Krystal Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Krystal Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Krystal Biotech has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Krystal Biotech's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Krystal Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Krystal Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Krystal Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

KRYS Management

 What is the CEO of Krystal Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Krish Krishnan
COMPENSATION $704,994
AGE 54
TENURE AS CEO 4.3 years
CEO Bio

Mr. Krish S. Krishnan, M.S., M.B.A. has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since December 2015. Mr. Krishnan is Co-Owner of Krishnan Family Trust. He served as the Chief Operating Officer of Intrexon Corporation from December 5, 2011 to March 21, 2016. Mr. Krishnan served as Chief Executive Officer and President of Pinnacle Pharmaceuticals, Inc. from 2009 to 2011. He served as the Chief Operating Officer, Head of Corporate Development and Director of Business Development and Strategy of Third Security, LLC. and served as its Senior Managing Director from 2001 to 2008. He served as Managing Principal at Ariba Inc. before joining Third Security. Mr. Krishnan was actively involved with a start-up venture. He has many years of experience in the life sciences industry. He served as Chief Operating Officer, Chief Financial Officer of New River Pharmaceuticals Inc. from April 2004 to April 2007. He served as Secretary of New River Pharmaceuticals Inc. since April 2004 and also served as its Principal Accounting Officer. He served as President and Chief Executive Officer of Harvest Pharmaceuticals Inc. Mr. Krishnan served with the management consulting firm A.T. Kearney, where he advised Fortune 50 companies on business strategy and started his career as an industrial engineer with E.I. Dupont de Nemours. He held position with KPMG Peat Marwick. He serves as a Director and Member of Advisory Board of Talkflow Systems, LLC. He serves as a Director of Pinnacle Pharmaceuticals, Inc. He has been Director of Thar Pharmaceuticals, Inc. since June 2016. He serves on the Boards of Directors of a number of Third Security's portfolio companies. He served as a Director of New River Pharmaceuticals Inc. from March 2003 to April 2007. He served as a Director of Biotie Therapies Corp. from 2008 to 2009. Mr. Krishnan received a B.S. in Mechanical Engineering from the Indian Institute of Technology (IIT), MS in Engineering from the University of Toledo and MBA in Finance from The Wharton School at the University of Pennsylvania.

CEO Compensation
  • Krish's compensation has increased whilst company is loss making.
  • Krish's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Krystal Biotech management team in years:

1.3
Average Tenure
  • The average tenure for the Krystal Biotech management team is less than 2 years, this suggests a new team.
Management Team

Krish Krishnan

TITLE
Chairman
COMPENSATION
$705K
AGE
54
TENURE
4.3 yrs

Suma Krishnan

TITLE
Founder
COMPENSATION
$495K
AGE
54
TENURE
4.3 yrs

Bo Lin

TITLE
Accounting Manager
TENURE
1.3 yrs

Kate Romano

TITLE
Chief Accounting Officer
TENURE
0.1 yrs

J. Naftzger

TITLE
Chief Legal Officer & Corporate Secretary
TENURE
0.1 yrs

Kat Tuminello

TITLE
Human Resources & Office Manager
TENURE
1.3 yrs

Josh Suskin

TITLE
Director of Human Resources & Operations

Jennifer Chien

TITLE
Chief Commercial Officer
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the Krystal Biotech board of directors in years:

3
Average Tenure
54
Average Age
  • The tenure for the Krystal Biotech board of directors is about average.
Board of Directors

Krish Krishnan

TITLE
Chairman
COMPENSATION
$705K
AGE
54
TENURE
4.3 yrs

Suma Krishnan

TITLE
Founder
COMPENSATION
$495K
AGE
54
TENURE
4.3 yrs

Dan Janney

TITLE
Independent Director
COMPENSATION
$163K
AGE
54
TENURE
3.3 yrs

Doug Norby

TITLE
Lead Independent Director
COMPENSATION
$134K
AGE
83

Dino Rossi

TITLE
Independent Director
COMPENSATION
$216K
AGE
65
TENURE
2.8 yrs

Kirti Ganorkar

TITLE
Non-Employee Director
AGE
52
TENURE
2.5 yrs

Julian Gangolli

TITLE
Independent Director
AGE
61
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. Sep 19 Sell Alta Bioequities Company 29. Aug 19 30. Aug 19 -88,684 $47.50 $-4,120,343
X
Management checks
We assess Krystal Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Krystal Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

KRYS News

Simply Wall St News

KRYS Company Info

Description

Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company’s lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Details
Name: Krystal Biotech, Inc.
KRYS
Exchange: NasdaqGM
Founded: 2015
$668,280,497
17,357,935
Website: http://www.krystalbio.com
Address: Krystal Biotech, Inc.
2100 Wharton Street,
Suite 701,
Pittsburgh,
Pennsylvania, 15203,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM KRYS Common Stock Nasdaq Global Market US USD 20. Sep 2017
BST 4KB Common Stock Boerse-Stuttgart DE EUR 20. Sep 2017
Number of employees
Current staff
Staff numbers
52
Krystal Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:35
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/11
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.